Diagonal Bio AB Third Quarter Report (Q3 2024)
Summary of Q3 report 2024
2024-07-01 — 2024-09-30 (July — September 2024)
● Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributed
with 248 KSEK (781 KSEK), and other operating income amounted to 0 KSEK (8 KSEK).
● Operating profit amounted to -1 242 KSEK (-2 605 KSEK).
● Operating profit per net weighted average share amounted to 0 SEK (-0.08 SEK).
● Cash flow during the third quarter amounted to -2 428 KSEK (-816 KSEK).
● Cash and cash equivalents at the end of the period amounted to 1 730 KSEK (4 717 KSEK).
Significant Events during the Third Quarter of 2024
● On August 21, 2024, Diagonal Bio received an order from the Technical University of Denmark for its LAMPlify® platform.
● On September 6, 2024, Diagonal Bio announced the successful external validation of LAMPlify® for respiratory viruses in horses.
● On September 27, 2024, Diagonal Bio announced the outcome of the exercise of warrants of series TO 1.
Significant Events after September 30, 2024
● On October 3, 2024, Diagonal Bio announced its partnership with StallZet and horse trainer Daniel Redén will conduct a pilot test using LAMPlify®.
● On October 8, 2024, Diagonal Bio announced that Hunneberga Horse Stable (Hunneberga Hästgård) initiated a partnership with Diagonal Bio to conduct a pilot test using LAMPlify®.
● On October 11, 2024, Diagonal Bio announced the successful external validation of LAMPlify® for viruses in pigs.
● On October 25, 2024 Diagonal Bio announced a pilot test of LAMPlify® at Norwegian University of Life Sciences.
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 31, 2024, at 08:00 CET.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.
